The Bacterial Cell Wall and Peptidoglycan

Peptidoglycan (murein, from Latin murus, "wall") is a heteropolymer built from two components: a sugar backbone and peptide crosslinks. The backbone consists of long glycan strands made of alternating N-acetylglucosamine (NAG or GlcNAc) and N-acetylmuramic acid (NAM or MurNAc), joined by β-1,4-glycosidic bonds. Muramic acid is peptidoglycan's signature sugar — a lactic acid ether attached to glucosamine — and it exists nowhere else in biology, which is why the whole polymer is essentially a bacterial fingerprint. Attached to the lactyl group of every MurNAc is a short peptide, typically four amino acids in the sequence L-alanine — D-glutamate — meso-diaminopimelic acid (or L-lysine) — D-alanine, initially synthesized with a fifth D-Ala (D-Ala-D-Ala at the terminus, later trimmed during crosslinking). Two features here defy the normal rules of protein biochemistry: the peptide contains D-amino acids, and it is assembled not by ribosomes but by dedicated cytoplasmic ligase enzymes, one amino acid at a time, on a nucleotide-sugar carrier. D-amino acids make the peptide resistant to nearly all host and environmental proteases, which are built to cleave only L-amino acid bonds — an elegant defense the cell wall exploits. The final and most important step is transpeptidation: an enzyme clips off the terminal D-Ala of one peptide's D-Ala-D-Ala tail and uses the energy of that bond to link the new terminal D-Ala to the diaminopimelic acid (or lysine) side chain of a peptide on a neighboring glycan strand (directly, or via a short peptide bridge in many Gram-positive species). Do this thousands of times across the whole cell surface and the individual glycan strands — each just a floppy 1-D polymer — become stitched into a single, continuous, bag-shaped macromolecule, the sacculus, that can in principle be isolated intact as one molecule per cell.

Step 1 — Cytoplasmic precursor synthesis. Peptidoglycan synthesis begins in the cytoplasm with UDP-activated sugars. UDP-GlcNAc is converted to UDP-MurNAc by adding an enolpyruvate group (from phosphoenolpyruvate) and reducing it — the enzyme MurA catalyzes the first committed step and is the target of the antibiotic fosfomycin. A series of ATP-dependent ligases (Mur ligases: MurC, MurD, MurE, MurF) then add the five amino acids one at a time to UDP-MurNAc, building UDP-MurNAc-pentapeptide — the "Park nucleotide," so named because Joseph Park identified it accumulating in penicillin-treated bacteria before its role was understood.

Step 2 — Lipid carrier and membrane translocation. UDP-MurNAc-pentapeptide is transferred onto a membrane-embedded lipid carrier called bactoprenol (undecaprenyl phosphate, a C55 isoprenoid), forming Lipid I. GlcNAc is then added to make Lipid II — the complete disaccharide-pentapeptide unit, still tethered to the membrane by the lipid anchor. Lipid II is flipped from the cytoplasmic face to the outer (periplasmic or external) face of the membrane by flippase proteins (MurJ in many bacteria), the only step in the pathway that physically crosses the membrane.

Step 3 — Polymerization. On the outer face, glycosyltransferases (either standalone SEDS-family proteins like RodA/FtsW, or the glycosyltransferase domain of bifunctional penicillin-binding proteins) extend the glycan strand by transferring the disaccharide-peptide unit onto the growing chain, releasing bactoprenol-pyrophosphate for recycling back across the membrane.

Step 4 — Transpeptidation (crosslinking). Penicillin-binding proteins (PBPs), membrane-anchored transpeptidases, catalyze the crosslinking reaction described above: cleaving D-Ala-D-Ala and forming a new peptide bond to a neighboring strand's third residue. This is the step β-lactam antibiotics block, by covalently acylating the PBP's active-site serine and mimicking the D-Ala-D-Ala substrate — the reason penicillin only kills growing, wall-synthesizing cells.

Step 5 — Remodeling. The mature sacculus is not static. Autolysins (murein hydrolases) continuously nick existing peptidoglycan to make room for new strand insertion during growth and division, a controlled "make-before-break" process; uncontrolled autolysin activity (as triggered by antibiotic-stalled synthesis) causes the cell to digest its own wall and lyse.

At the whole-cell scale, the wall's job is mechanical: it converts an isotropic internal turgor pressure into a defined shape by resisting stretch anisotropically. In rod-shaped bacteria like Escherichia coli, the glycan strands run mostly circumferentially (hoop-like) around the cylinder, while peptide crosslinks run more axially — a fiber arrangement mechanically analogous to a fiber-reinforced pressure vessel, making the cylinder resist circumferential stretch more than the poles resist axial stretch, which is part of why rods elongate rather than balloon.

This structural difference — thick single-layer wall with teichoic acids in Gram-positive bacteria versus thin wall sandwiched beneath an outer membrane in Gram-negative bacteria — is exactly what the Gram stain visualizes, and it foreshadows why some antibiotics (e.g., vancomycin) cannot cross the Gram-negative outer membrane to reach their target at all.

Lysozyme and the discovery of the wall as a discrete molecule (Alexander Fleming, 1922; further biochemistry by Karl Meyer and others through the 1930s–1960s). Fleming noticed that his own nasal mucus and tears could dissolve certain bacteria, and traced the activity to an enzyme he named lysozyme. Lysozyme was later shown to be a glycosidase that cleaves specifically the β-1,4 bond between NAM and NAG — proving the backbone was a sugar polymer with this exact linkage, since only that bond's hydrolysis released soluble fragments and caused bacteria to lyse (in hypotonic medium) or survive as fragile, wall-less "protoplasts" (in isotonic/hypertonic medium held at matched osmotic pressure with sucrose). The osmotic-protection experiment was itself decisive: if bacteria are digested by lysozyme in an isotonic sucrose solution, they survive as spherical protoplasts that burst the instant they're returned to dilute buffer — direct proof that the wall, not the membrane, was what had been resisting osmotic lysis.

Park's nucleotide and the discovery of the biosynthetic pathway (Joseph T. Park, 1952). Working at Duke and then Washington University, Park treated Staphylococcus aureus with sub-lethal doses of penicillin and noticed the cells accumulated large quantities of small, water-soluble UDP-linked nucleotides that were absent from untreated cells — compounds that came to be called the "Park nucleotides." At the time nobody knew what these were for. It took until the work of Jack Strominger and colleagues in the late 1950s and 1960s to show that these accumulating nucleotides were exactly the cytoplasmic peptidoglycan precursors (UDP-MurNAc-pentapeptide and related intermediates) — meaning penicillin was blocking a late, extracytoplasmic step (transpeptidation) while synthesis of the precursors upstream continued unchecked, causing them to pile up. This was the first direct biochemical evidence that penicillin's target was cell wall synthesis specifically, and it mapped the pathway that Steps 1–4 above describe.

Confirming the transpeptidase target: Tipper and Strominger (1965). Donald Tipper and Jack Strominger proposed and then demonstrated that penicillin's β-lactam ring is a structural mimic of the D-alanyl-D-alanine terminus of the peptidoglycan precursor. They showed that penicillin covalently and irreversibly acylates the active-site serine of the transpeptidase enzyme, exactly as D-Ala-D-Ala would be attacked during normal crosslinking, but the resulting penicilloyl-enzyme complex cannot be hydrolyzed and turned over — permanently inactivating the enzyme. This explained, at the molecular level, why penicillin is bactericidal specifically against actively dividing, wall-synthesizing cells and why later X-ray crystallography confirmed the physical resemblance between the β-lactam ring and the D-Ala-D-Ala dipeptide.

Isolating the sacculus as one molecule (electron microscopy and biochemical isolation, 1950s onward, notably by Cyril Weibull and later Uli Schwarz/Joachim-Volker Höltje). Treating bacteria with SDS (which dissolves membranes and denatures nearly all protein) and other harsh detergents leaves behind an intact, cell-shaped, insoluble bag — the isolated sacculus — that retains the size and shape of the original bacterium even after every membrane and cytoplasmic component has been stripped away. This was direct physical proof that peptidoglycan alone, and nothing else, is sufficient to hold the cell's shape, and that it truly forms one continuous covalent network rather than a loose stack of independent glycan chains.

Example 1 — Turgor pressure and wall failure threshold. A rod-shaped Gram-negative bacterium has an internal turgor pressure of about 3 atmospheres (≈304 kPa) above the external medium, a radius of 0.5 μm, and a peptidoglycan layer 3 nm thick. Treat the cylindrical wall as a thin-walled pressure vessel. The circumferential (hoop) stress in a thin-walled cylinder is: σ = (P × r) / t Plugging in P = 304,000 Pa, r = 0.5 × 10⁻⁶ m, t = 3 × 10⁻⁹ m: σ = (304,000 × 0.5×10⁻⁶) / (3×10⁻⁹) ≈ 5.07 × 10⁷ Pa ≈ 50 MPa This ~50 MPa hoop stress is in the same range as reported peptidoglycan tensile strength estimates (tens of MPa), consistent with the wall operating close to, but safely under, its mechanical limit under normal turgor — and explains why even modest enzymatic thinning (lysozyme partially digesting the wall) or synthesis inhibition (a β-lactam blocking new crosslink formation, so existing crosslinks are diluted out during growth) is enough to push local stress past the failure point and cause lysis. It also shows why Gram-negative cells, with a much thinner wall than Gram-positive cells, tend to run somewhat lower turgor pressures (~3–5 atm) than Gram-positive cells (~15–25 atm), whose much thicker peptidoglycan can bear far higher hoop stress.

Example 2 — Reading a penicillin-susceptibility phenotype. A clinical microbiologist isolates two bacterial strains from a wound culture. Strain A is a Gram-positive coccus that lyses completely within 30 minutes of adding a β-lactam antibiotic in dilute broth. Strain B is a Gram-negative rod with an identical PBP transpeptidase (confirmed by sequencing) that survives the same treatment unharmed. Reasoning: since the drug target itself (the transpeptidase) is identical and sensitive in a cell-free assay, the difference must lie in access, not in mechanism. Gram-negative Strain B possesses an outer membrane outside the thin peptidoglycan layer; if this strain also expresses efflux pumps or a β-lactamase in its periplasm, the drug is either pumped out before reaching its target or hydrolyzed in the periplasmic space before it can acylate the transpeptidase's active-site serine. This scenario mirrors real clinical logic: it is why many β-lactams that easily kill Gram-positive pathogens (e.g., Staphylococcus, Streptococcus) require porin-permeable, β-lactamase-resistant chemistry (or a β-lactamase inhibitor added alongside) to work against Gram-negative pathogens like Pseudomonas or Klebsiella — the wall chemistry is the same target, but the envelope architecture surrounding it changes whether the drug ever arrives.

Joseph Tal Park (1921–1990) was an American biochemist working at Duke University Medical School when he made the observation that would eventually crack open cell wall biosynthesis. In the early 1950s, penicillin's clinical success was already well established, but nobody knew, at the molecular level, what the drug actually blocked inside the cell. Park was studying nucleotide metabolism in Staphylococcus aureus using paper chromatography — a painstaking, low-throughput technique by modern standards — when he noticed that penicillin-treated cultures accumulated several previously undescribed UDP-linked compounds in large quantity, compounds entirely absent from untreated cultures. He had no way, at the time, to know these were peptidoglycan precursors; that identification required another decade of structural work, principally by Jack Strominger's laboratory, which showed the accumulating "Park nucleotides" were UDP-MurNAc-peptides — the exact cytoplasmic intermediates in wall precursor synthesis described above. Park's chromatographic accident thus became the thread that, once pulled by Strominger, Tipper, and others, unraveled the entire peptidoglycan biosynthetic pathway and pinpointed transpeptidation as penicillin's molecular target.

Every β-lactam antibiotic in clinical use — penicillins, cephalosporins, carbapenems, monobactams — works by exploiting exactly the transpeptidation step mapped out above, and understanding PBP structure has driven rational design of newer agents (e.g., carbapenems effective against many β-lactamase-producing organisms). Vancomycin, a glycopeptide, works one step earlier: it binds the D-Ala-D-Ala terminus of the pentapeptide itself, physically blocking the transpeptidase and transglycosylase from acting on it — the molecular basis of vancomycin resistance (VanA-type) is bacterial replacement of the terminal D-Ala with D-lactate, which vancomycin binds a thousand-fold more weakly. Fosfomycin blocks MurA at the very first committed step. Bacitracin blocks recycling of the bactoprenol lipid carrier. Each drug class corresponds to a distinct, mechanistically dissected step in the pathway described here, which is precisely why understanding peptidoglycan synthesis in molecular detail remains central to designing new antibiotics as resistance spreads. Beyond antibiotics, lysozyme's specificity for the NAG-NAM bond makes it a component of innate immune defense in tears, saliva, and mucus, and a food-industry additive used to control bacterial spoilage in cheese and wine. Peptidoglycan fragments themselves are potent immune activators: host pattern-recognition receptors such as NOD1 and NOD2 detect specific muropeptide fragments (from Gram-negative and Gram-positive-type peptidoglycan respectively), triggering inflammatory signaling — meaning peptidoglycan chemistry is directly read out by the human innate immune system, and mutations in NOD2 are linked to Crohn's disease susceptibility. In agriculture and biotechnology, engineered phage-derived peptidoglycan hydrolases ("endolysins") are being developed as alternatives to antibiotics for controlling bacterial pathogens in livestock and in phage therapy for antibiotic-resistant infections, directly exploiting the same NAM-NAG bond that Fleming's lysozyme cleaves.

Ask the tutor: How do the elongasome and divisome coordinate peptidoglycan synthesis to switch a bacterium from growing longer to dividing in two?